GeneDx Holdings Corp. - Class A Common Stock (WGS)

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced findings from the Genetic Sequencing Analysis has Value in Economic Savings (SAVES)-Kids Study, a real-world data Health Economics and Outcomes Research (HEOR) analysis led by GeneDx that focuses on the economic impact of whole exome sequencing (WES) and whole genome sequencing (WGS) in children with neurodevelopmental disorders, like epilepsy and developmental delay and intellectual disability (DD/ID). The data was unveiled today at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting in Baltimore, MD.

Ark Invest's CEO kicked off the new trading week with a little shopping.

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing Program is designed to expand access to GeneDx’s industry-leading ExomeDx™ test for patients with suspected Niemann-Pick disease type C, helping clinicians reach accurate diagnoses faster and guide clinical decision-making. De-identified data from the program will be added to GeneDx Infinity™, the largest and most comprehensive rare disease dataset, to help drive faster diagnoses of NPC to help patients and providers make informed treatment decisions.

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced scientific contributions to be presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Meeting. GeneDx will present 18 accepted abstracts, including three platform presentations and two rapid fire poster talks, with research spanning sequencing innovations, breakthroughs in AI-supported interpretation, novel gene-disease discoveries, the real-world impact of earlier diagnoses, and more.

Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.

This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.

MDU Resources Group supplies regulated utilities and construction services across the U.S., with consistent revenue and a stable dividend.

AI-powered health intelligence firm GeneDx Holdings reported a notable insider sale as it advances its clinical data analytics platform.

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences:

GeneDx (WGS) Q4 2025 Earnings Call Transcript

Insert the "Software and interpretation services" row in the Volume & Revenue(1) table.

Power Solutions International designs and manufactures advanced engines and power systems for industrial and transportation markets.

This SaaS firm delivers cloud-based business software worldwide, focusing on subscription-driven customer and IT service solutions.

Air Lease Corporation provides global airlines with commercial jet leasing, sales, and fleet management services across a diverse portfolio.

Five9 delivers cloud-based contact center software for enterprises, serving clients across finance, healthcare, and technology sectors.

Freshworks delivers cloud-based SaaS solutions for customer engagement, IT service management, and business process automation.

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its President and Chief Executive Officer Katherine Stueland has been named to the TIME100 Health 2026 list – TIME’s annual recognition of the 100 individuals who most influenced global health over the past year.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the fourth quarter of 2025 before the market opens on Monday, February 23, 2026. Management will host a conference call that day to discuss fourth quarter 2025 financial and operating results at 8:30 a.m. Eastern Time.

The stark divide in the financial markets reached a fever pitch today, January 29, 2026, as the long-anticipated "Great Rotation" finally appeared to take hold. While the tech-heavy Nasdaq Composite and the broader S&P 500 were dragged into the red by a staggering sell-off in artificial intelligence bellwethers, the

The dawn of 2026 has brought a seismic shift to global equity markets, as the long-anticipated "Great Rotation" finally takes hold. After nearly three years of dominance by a handful of mega-cap technology titans, investors are aggressively reallocating capital toward small-cap and mid-cap sectors. This movement has created a stark

As of January 27, 2026, the global financial markets are witnessing a profound transformation in the artificial intelligence narrative. While 2023 and 2024 were defined by a "land grab" for semiconductor chips and massive data center construction, the narrative in early 2026 has shifted toward the "Second Wave": a period

As of January 26, 2026, the financial landscape has undergone a seismic shift, marking the definitive end of the "Magnificent 7" era of uncontested dominance. For the first time in decades, the baton of market leadership has been passed to the small-cap arena in what analysts are calling the "Earnings

As of January 26, 2026, the long-standing hierarchy of the U.S. equity markets is undergoing its most significant transformation since the post-pandemic recovery. For the first time in years, the narrative of "mega-cap exceptionalism" is being challenged by a resurgent small-cap sector. Wall Street analysts are calling this the

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.